A new collaboration between researchers at RCSI and Trinity College Dublin (TCD) as part of the AMBER, SFI-funded materials science centre in conjunction with Integra LifeSciences, a world leader in medical technology, aims to develop, and bring to the market, a new product to facilitate the repair of large nerve defects in the body. This €1.4 million research programme will run for three years.

This project is led by Prof. Fergal O’Brien (Dept. of Anatomy, RCSI & Deputy Director in AMBER) in partnership with Prof. Conor Buckley from the Trinity Centre for Bioengineering (TCD).

Peripheral nerves link the brain and spinal cord to the other parts of the body, such as the muscles and skin. They can be damaged through disease, trauma and burns resulting in interference with the brain's ability to communicate with tissues resulting in the loss of motor or sensory function to muscles and skin. This can have significant deterioration in a patient’s quality of life. 

Peripheral nerve injury is a major clinical problem and is known to affect more than 5 million people worldwide every year. It is estimated that five percent of multiple trauma patients have peripheral nerve injuries. Prompt surgical intervention is needed but if the injury size is larger than five millimetres, the primary treatment option available in most cases is by autograft which involves removal of nerve tissue from another part of the patient’s body and transplantation to the site of injury.  Unfortunately, autografts are hampered by a number of issues including the limited availability of donor tissue and often functional recovery for patients can be poor. As a result the RCSI & TCD team in AMBER are working with Integra LifeSciences to develop a next generation nerve graft capable of repairing large nerve defects without the need for invasive secondary surgeries.

RCSI’s collaboration with Integra began in 2005 and has deepened in the intervening years through the AMBER Centre.  This current project marks the second engagement in the area of peripheral nerve repair between the parties. The first project was successfully completed at the end of 2016 and resulted in a patent being filed on technology generated under the project.  This current engagement builds on this research. 

Dr Simon Archibald, Vice President and Chief Scientist from Integra LifeSciences said: “The demand for nerve repair biomaterials is increasing due to the aging population and rising number of nerve injuries and nerve surgeries. Our aim is to treat largescale nerve defects in the body and introduce this new technology to our portfolio of existing nerve repair products.”

Prof. Fergal O’Brien, Professor of Bioengineering & Regenerative Medicine & Deputy Director of AMBER said: “Building on a wealth of expertise in biomaterials development from the Tissue Engineering Research Group at RCSI, our hope is to work with Integra to see this new technology translate to the benefit of patients and society.”

About RCSI

RCSI is ranked in the top 250 institutions worldwide in the Times Higher Education World University Rankings (2016-2017). It is an international not-for-profit health sciences institution, with its headquarters in Dublin, focused on education and research to drive improvements in human health worldwide.

About AMBER

AMBER (Advanced Materials and BioEngineering Research) is a Science Foundation Ireland funded centre which provides a partnership between leading researchers in materials science and industry to develop new materials and devices for a range of sectors, particularly the ICT, medical devices and industrial technology sectors. The centre is hosted in Trinity College Dublin, working in collaboration with CRANN (Centre for Research on Adaptive Nanostructures and Nanodevices), the Trinity Centre for Bioengineering and with University College Cork and the Royal College of Surgeons of Ireland.

About Integra

Integra LifeSciences is a global leader in medical technology with more than 3,700 people worldwide. Its manufacturing base in Tullamore, Co. Offaly employs more than 125 people. Integra is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care.  Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, and orthopedics and tissue technologies.